SBIR Reauthorization 2026: New Rules, $30M Awards, and What Changes for Applicants

After five months of congressional paralysis, the longest lapse in the 43-year history of America's flagship small business innovation programs, the Senate moved with sudden velocity on February 25 to broker a deal that not only restarts the SBIR and STTR programs but rewrites their operating rules in ways that will reshape how small companies compete for federal R&D dollars through the end of the decade.

The Small Business Innovation and Economic Security Act, introduced by Senators Edward Markey (D-Mass.) and Joni Ernst (R-Iowa), was hot-lined in the Senate the same afternoon — a procedural maneuver that skips committee markup and sets up passage by unanimous consent. The House is expected to take up the bill next week, and the legislative path to the president's desk appears clear.

For the roughly 6,000 small businesses that win SBIR or STTR awards in a typical year, the restart is the headline. But the fine print is where the real story lives. This is not a clean extension. It is a structural overhaul with provisions that will change who can apply, how many proposals a company can submit, and how much money is on the table for firms that prove they can move technology from the lab to the market.

Five Months That Changed the Conversation

The SBIR and STTR programs expired on September 30, 2025, when Congress failed to include reauthorization language in any of the legislative vehicles moving through the session. For five months, 11 federal agencies — including the Department of Defense, NIH, NSF, DOE, and NASA — could not issue new solicitations or make new awards. Existing contracts continued, but the front door was locked.

The lapse was not an oversight. Three competing bills — a clean one-year House extension (H.R. 5100), Markey's reform package, and Ernst's more aggressive INNOVATE Act — pulled in different directions on the central question: how aggressively should Congress restructure the programs while keeping them alive?

The compromise resolves that tension by adopting Markey's framework with enough Ernst-backed security provisions to bring conservative members along. The result is a bill that extends authorization through September 30, 2031 — a full five years, eliminating the three-year reauthorization cycles that have produced recurring crises — while introducing the most significant programmatic changes since the STTR program was created in 1992.

Strategic Breakthrough Awards: $30 Million and a New Commercialization Pathway

The single most consequential provision in the bill is the creation of Strategic Breakthrough Awards, a new post-Phase II funding mechanism that allows agencies to make awards up to $30 million with performance periods of up to 48 months.

This is a dramatic departure from the traditional SBIR architecture. Phase I awards — proof of concept — typically cap at $150,000 to $275,000 depending on the agency. Phase II awards — full R&D — generally range from $750,000 to $1.75 million. The gap between Phase II and viable commercial production has been the program's most persistent failure mode, frequently called the "valley of death."

Strategic Breakthrough Awards are designed to bridge that gap. But they come with constraints that will filter out most applicants. To qualify, a company must hold at least one prior Phase II award. It must demonstrate 100 percent matching funds from qualifying sources — private investment, non-SBIR government contracts, or revenue. For defense-related awards, at least 20 percent of the match must come from non-SBIR Department of Defense sources.

The total pool is capped at 0.50 percent of each agency's extramural R&D budget, ensuring the program supplements rather than cannibalizes the core Phase I and Phase II pipeline. For DoD, which controls the largest SBIR allocation, that cap translates to roughly $100-150 million annually. For NIH, it's closer to $80-100 million.

The matching requirement is the sharpest filter. Companies that have raised venture capital or secured follow-on defense contracts will have a significant advantage. Pure research shops — university spinouts and bootstrap-funded technical teams — will need to build commercial relationships before they can access these awards.

Foreign Risk Screening: Every Application Gets Reviewed

The security provisions reflect years of concern about foreign government-linked entities winning SBIR awards and using federally funded technology for adversarial purposes. The bill does not ban foreign-connected companies outright, but it creates a mandatory screening framework that goes well beyond anything the programs have required before.

Every SBIR and STTR application will now undergo a due diligence review covering cybersecurity practices, patent portfolios, employee backgrounds, and financial ties to "foreign countries of concern." The screening will check applicants against enumerated federal watchlists.

The bill includes a critical safeguard: when an agency denies an application based on a security-risk determination, it must provide written notice explaining the basis for the denial. Denials do not permanently bar companies from future eligibility. This notice-and-appeal structure reflects Markey's concern that overly broad security restrictions could freeze out legitimate small businesses with incidental foreign connections — a researcher who trained at a Chinese university, for example, or a company with a European investor.

For small businesses, the practical implication is clear: know your ownership structure, your patent assignments, and your employees' foreign affiliations before you submit. The screening will add processing time to every application, and companies that cannot document clean backgrounds will face delays even if they ultimately pass.

Proposal Caps: The End of SBIR Mills

The bill takes direct aim at "multi-award winners" — companies that submit dozens or hundreds of proposals across agencies and win outsized shares of the total SBIR pool. Critics have long argued that a handful of firms have turned SBIR into a permanent revenue stream, crowding out genuine early-stage innovators. Defenders counter that these firms deliver reliable, high-quality research and represent exactly the kind of sustained R&D capacity the programs were designed to build.

The compromise does not impose a hard ceiling on total awards but gives each agency's SBIR/STTR director the authority to set annual proposal limits. Each director chooses the method — per fiscal year, per solicitation, or per topic — but the limit must apply equally to all firms. No company gets special treatment.

Waivers are permitted only for "time-sensitive and urgent" topics, require written justification and senior approval, and are capped at 5 percent of topics annually. This structure effectively lets agencies throttle high-volume submitters without the political complexity of naming specific companies.

For smaller firms that have struggled to compete against well-resourced incumbents, this is arguably the most impactful provision in the bill. If NIH limits firms to, say, 15 Phase I proposals per year, the landscape for first-time applicants widens materially.

What Else Changes

Several smaller provisions add up to meaningful structural shifts:

Administrative spending. The bill raises the cap on agency administrative spending from 3 percent to 3.3 percent of SBIR funds and extends this allowance for 20 years. The additional resources are earmarked for outreach in rural areas and underrepresented regions, evaluation of program outcomes, and fraud detection.

Fellowship programs. Agencies are directed to launch SBIR/STTR fellowship programs at universities and national laboratories, designed to cultivate young science talent and connect them to the entrepreneurial ecosystem before they leave academic research.

Phase III training. The bill mandates acquisition workforce training on Phase III agreements — the follow-on production and services contracts that convert SBIR-funded R&D into fielded capabilities. Standardized contracting tools and model contracts will be developed and made available government-wide, addressing a chronic complaint from companies that Phase III processes vary wildly across contracting offices.

Data tracking. Enhanced reporting requirements will funnel more granular data into federal procurement systems, improving Congress's ability to monitor who is winning awards, how funding is distributed geographically, and whether commercialization outcomes are meeting benchmarks.

What Small Businesses Should Do Right Now

The bill has not yet received a presidential signature, but the bipartisan pathway is clear enough to begin preparation.

Audit your foreign connections. Walk through your cap table, your patent assignments, your employee roster, and your subcontractor agreements. Identify any ties to foreign countries of concern. If you have legitimate connections that might trigger a flag, prepare documentation explaining the nature and scope of each relationship. It is far better to address these proactively than to face a mid-review delay.

Count your proposals. If your firm has historically submitted 20, 30, or more proposals per year, recognize that agency-level caps will likely reduce your submission volume. Prioritize the topics where your technical capabilities are strongest and your commercialization story is most credible.

Model the Strategic Breakthrough pathway. If your company holds a Phase II award and has commercial traction — revenue, private investment, or non-SBIR government contracts — start modeling a Strategic Breakthrough proposal now. Identify the matching funds you could bring to the table and the 48-month milestone structure that would govern a $30 million award.

Prepare for fast reopening. When the bill passes, agencies will move to recover five months of lost solicitation cycles. Companies with updated technical narratives, current biosketches, and refined commercialization plans will have an advantage in the first wave of new competitions. Do not wait for the solicitation to start writing.

The five-month shutdown of SBIR and STTR will be remembered as the crisis that forced a long-overdue modernization of the programs. The new law gives small businesses access to larger awards, clearer pathways to production, and a more level competitive field — but only if they understand the new rules before the starting gun fires.

For a practical checklist on what to do before the first solicitations drop, see how to prepare for the SBIR restart.

For companies tracking the timeline and identifying alternative funding during the transition, Granted monitors federal, state, and foundation opportunities across 144 sources, including the SBIR and STTR programs that are about to come back to life.